FAA Marijuana Aviation Standards: Pilots, Air Traffic Controllers & Policy

Executive Summary

The Federal Aviation Administration is evaluating new marijuana testing and employment standards for pilots and air traffic controllers following the Trump administration's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. This regulatory review represents the first comprehensive examination of aviation safety protocols in relation to cannabis since the substance was classified alongside heroin in 1970. The FAA's current zero-tolerance policy prohibits any marijuana use by safety-sensitive aviation personnel, regardless of state legalization status or medical authorization. With cannabis rescheduling creating a new legal framework under 21 U.S.C. § 812, the agency faces pressure to modernize standards while maintaining the aviation industry's exceptional safety record. The outcome will affect approximately 700,000 certificated pilots, 14,000 air traffic controllers, and tens of thousands of aircraft mechanics and other aviation workers currently subject to Department of Transportation drug testing requirements under 49 CFR Part 40.

Why This Matters

The FAA's marijuana policy review carries implications for aviation safety, workforce availability, medical privacy, and the broader federal response to state-level cannabis legalization. The aviation industry faces a documented pilot shortage, with regional airlines particularly affected. The Air Line Pilots Association has reported that mandatory retirement ages and training pipeline constraints have created workforce gaps that could worsen if qualified candidates continue to be excluded for past marijuana use. According to the FAA's own data, the agency issued 164,718 new pilot certificates in 2025, but airlines project needing 14,500 new pilots annually through 2030 to meet demand and replace retirements. Air traffic controller staffing presents similar challenges. The National Air Traffic Controllers Association has identified staffing levels at approximately 85% of optimal capacity at many facilities, with some towers operating with minimum crews. The FAA's Academy in Oklahoma City graduates roughly 1,500 new controllers annually, but attrition and retirements create ongoing gaps. Current FAA regulations require pilots to report any drug-related motor vehicle action within 60 days, and the agency conducts approximately 350,000 random drug tests annually across the aviation workforce. Positive marijuana tests result in immediate certificate action, typically revocation or long-term suspension requiring extensive rehabilitation documentation before reinstatement consideration. The financial stakes extend beyond workforce issues. Aviation contributes approximately $1.8 trillion to the U.S. economy annually, according to the FAA's economic impact analysis. Any policy change affecting safety protocols faces intense scrutiny from airlines, insurance carriers, and the traveling public. Conversely, maintaining prohibition while 38 states have legalized medical cannabis and 24 have approved adult-use programs creates legal tensions and workforce recruitment barriers. Patient advocates argue that current policies discriminate against individuals using state-legal medical marijuana for conditions like PTSD, chronic pain, and epilepsy. Veterans groups have particularly emphasized that former military pilots who use VA-recommended cannabis for service-connected disabilities face permanent career disqualification, despite no evidence of impairment during duty hours.

Background and History

The FAA's marijuana prohibition originated with the Controlled Substances Act of 1970 and has remained essentially unchanged despite five decades of evolving cannabis policy at state and international levels.

The Controlled Substances Act and Initial Aviation Rules (1970-1985)

When Congress passed the Controlled Substances Act in 1970, marijuana was placed in Schedule I alongside heroin, LSD, and peyote. The classification defined cannabis as having "no currently accepted medical use" and "high potential for abuse" under 21 U.S.C. § 812(b)(1). The FAA, then a relatively young agency created by the Federal Aviation Act of 1958, incorporated this classification into its medical certification standards. The agency's initial approach focused primarily on alcohol, which had been recognized as an aviation safety concern since the earliest days of flight. The Civil Aeronautics Act of 1938 had given federal authorities power to regulate pilot fitness, and alcohol-related accidents in the 1960s and 1970s drove policy development. Marijuana received less attention until recreational use increased during the 1970s. In 1975, the FAA published Advisory Circular 60-22, which first explicitly addressed marijuana use by pilots. The guidance stated that any use of marijuana was disqualifying for medical certification, establishing a zero-tolerance approach that contrasted with the more nuanced alcohol policies allowing consumption when not flying.

Drug-Free Workplace Act and DOT Testing Mandate (1986-1995)

The landscape shifted dramatically with President Reagan's 1986 Executive Order 12564, which established drug-free workplace requirements for federal contractors and safety-sensitive positions. Congress followed with the Drug-Free Workplace Act of 1988, and the Department of Transportation issued comprehensive drug testing regulations in 1989. The Omnibus Transportation Employee Testing Act of 1991 mandated drug and alcohol testing for safety-sensitive transportation workers, including all FAA-certificated aviation personnel. The implementing regulations, codified at 49 CFR Part 40, established the testing protocols still in use today: pre-employment screening, random testing at 25% annually for drugs, reasonable suspicion testing, post-accident testing, and return-to-duty testing. The FAA's drug testing program began full implementation in 1995. The agency established a Medical Certification Division within the Office of Aerospace Medicine to handle cases involving substance use. The division developed the protocols for Special Issuance medical certificates, which allow pilots with disqualifying conditions to fly under specific limitations after demonstrating mitigation. Marijuana cases, however, received no such accommodation. A single positive test or admission of use resulted in certificate revocation. Reinstatement required complete abstinence documentation, typically including two years of random observed testing, substance abuse evaluation, and psychological assessment.

State Medical Marijuana Laws Create Conflict (1996-2012)

California's Proposition 215 in 1996 created the first direct conflict between state and federal aviation policy. The Compassionate Use Act allowed patients with physician recommendations to possess and use marijuana for medical purposes. The FAA immediately clarified that state law provided no protection for pilots or air traffic controllers. In 1997, the FAA issued a notice to airmen (NOTAM) stating that marijuana use remained prohibited for all certificated personnel regardless of state law or medical authorization. The agency's position was that federal law preempted state authorization, and that the safety-sensitive nature of aviation required absolute prohibition. As additional states adopted medical marijuana programs—Oregon and Washington in 1998, Colorado and Nevada in 2000—the FAA maintained its stance. The agency's 2008 guidance to Aviation Medical Examiners explicitly instructed them to defer or deny medical certificates for any applicant reporting marijuana use, even with state medical authorization. The conflict intensified after Gonzales v. Raich in 2005, when the Supreme Court held that federal marijuana prohibition was constitutional under the Commerce Clause even for intrastate medical use. The decision strengthened the FAA's legal position that federal aviation safety regulations superseded state marijuana laws.

Adult-Use Legalization and Workforce Pressure (2012-2020)

Colorado and Washington's 2012 voter approval of adult-use marijuana legalization marked a new phase. By 2020, eleven states had legalized recreational cannabis, and 33 had medical programs. The FAA faced increasing questions about whether its policies reflected current science on cannabis impairment and detection. The agency's drug testing protocols detect THC metabolites for days or weeks after use, long after any psychoactive effects have dissipated. Critics argued this was fundamentally different from alcohol testing, which measures current impairment. A pilot who used marijuana on a Saturday evening would test positive the following Friday, despite no impairment during the intervening flights. Aviation industry groups began requesting policy reviews. In 2019, the Regional Airline Association submitted comments to the FAA noting that pilot shortage concerns were exacerbated by disqualification of otherwise qualified candidates for past marijuana use. The association stopped short of recommending policy changes but urged the agency to examine whether current standards were appropriately calibrated to safety risks. The National Business Aviation Association conducted a 2020 survey finding that 23% of corporate flight departments reported difficulty finding qualified pilots, with drug testing policies cited as a contributing factor. However, airline pilot unions generally supported maintaining strict standards, with the Air Line Pilots Association stating that any relaxation of drug prohibitions could compromise safety culture.

COVID-19, Hemp Legalization, and Testing Complications (2020-2024)

The 2018 Farm Bill's legalization of hemp—cannabis with less than 0.3% THC—created unexpected complications for aviation drug testing. Products marketed as CBD-only sometimes contained trace THC amounts sufficient to trigger positive drug tests. The FAA issued a 2020 notice warning pilots that CBD use could result in positive tests and certificate action, even though hemp-derived CBD was federally legal. Several pilots challenged certificate revocations after testing positive for THC while claiming only CBD use. In administrative law judge proceedings, the FAA maintained that regardless of intent or product labeling, any confirmed positive test for marijuana metabolites was disqualifying. The National Transportation Safety Board upheld these revocations in multiple cases between 2021 and 2023. The COVID-19 pandemic temporarily reduced aviation activity but worsened the pilot shortage as airlines offered early retirement packages and training slowed. As travel rebounded in 2022-2023, workforce constraints became acute. Regional airlines canceled routes due to insufficient crews, and the major carriers increased starting pay to attract candidates.

Rescheduling Process Begins (2024-2026)

In August 2024, the Department of Health and Human Services recommended to the Drug Enforcement Administration that marijuana be rescheduled from Schedule I to Schedule III. The recommendation followed a comprehensive review mandated by President Biden in 2022. Schedule III substances, which include ketamine, anabolic steroids, and testosterone, are defined as having "moderate to low potential for physical and psychological dependence" and accepted medical uses under 21 U.S.C. § 812(b)(3). The DEA published a Notice of Proposed Rulemaking in December 2024, initiating a public comment period that drew more than 45,000 submissions. Aviation industry stakeholders submitted detailed comments. The Aircraft Owners and Pilots Association urged the FAA to begin parallel review of its medical certification standards. The National Air Traffic Controllers Association requested clarity on how rescheduling would affect DOT testing requirements. In January 2026, the Trump administration took office with stated support for marijuana rescheduling. The DEA published its final rule in March 2026, officially moving cannabis to Schedule III effective May 1, 2026. The rule specified that the rescheduling did not alter the illegal status of marijuana under federal law for non-medical purposes, but acknowledged accepted medical uses. The FAA announced in June 2026 that it was conducting a comprehensive review of its marijuana-related policies in light of the rescheduling. The agency formed a working group including representatives from the Office of Aerospace Medicine, Flight Standards Service, and Air Traffic Organization, with consultation from the Department of Transportation's Office of Drug and Alcohol Policy and Compliance.

Key Players

Federal Aviation Administration

The FAA holds regulatory authority over all aspects of civil aviation safety under 49 U.S.C. § 44701. The agency's Administrator, appointed by the President and confirmed by the Senate, oversees approximately 45,000 employees and a budget exceeding $18 billion. The Office of Aerospace Medicine, led by the Federal Air Surgeon, manages medical certification for approximately 700,000 pilots and determines fitness standards. The FAA's current position, as stated in its July 2026 statement, is that marijuana remains prohibited for safety-sensitive aviation personnel pending completion of the policy review. The agency has not provided a timeline for completing the review but indicated it would involve consultation with medical experts, toxicologists, and aviation safety specialists.

Drug Enforcement Administration

The DEA's rescheduling decision created the impetus for the FAA's review. The agency's final rule moving marijuana to Schedule III acknowledged that cannabis has accepted medical uses, fundamentally changing the legal framework that underpinned aviation prohibition. However, the DEA emphasized that rescheduling did not legalize marijuana or alter criminal penalties for unauthorized possession and distribution.

Department of Transportation

The DOT's Office of Drug and Alcohol Policy and Compliance administers the drug testing program covering all transportation modes under 49 CFR Part 40. The office has stated that marijuana remains a prohibited substance for DOT-regulated testing regardless of rescheduling, but acknowledged that the FAA has authority to modify aviation-specific medical standards.

National Transportation Safety Board

The NTSB investigates aviation accidents and serves as the appellate body for FAA certificate actions. The board has consistently upheld marijuana-related certificate revocations, finding that the FAA's zero-tolerance policy is rationally related to safety. Any policy change by the FAA would likely face NTSB scrutiny in future enforcement cases.

Air Line Pilots Association

ALPA represents approximately 78,000 pilots at 41 airlines in the United States and Canada. The union has historically supported strict drug and alcohol standards, viewing them as essential to maintaining public confidence and safety culture. In comments submitted to the FAA in July 2026, ALPA stated that any policy modifications must be supported by peer-reviewed research on impairment and safety outcomes.

Aircraft Owners and Pilots Association

AOPA represents more than 300,000 general aviation pilots and aircraft owners. The association has advocated for medical certification reform, successfully pushing for the BasicMed program that allows certain pilots to fly without FAA medical certificates. AOPA's position on marijuana policy is that past use should not be permanently disqualifying if pilots can demonstrate current abstinence and fitness.

National Air Traffic Controllers Association

NATCA represents approximately 20,000 air traffic controllers and other aviation safety professionals. The union has emphasized that controller staffing shortages must not lead to compromised safety standards, but has requested that the FAA examine whether current marijuana policies are evidence-based and appropriately calibrated.

Regional Airline Association

RAA represents regional airlines that operate approximately 41% of scheduled commercial flights in the United States. The association has documented severe pilot shortages affecting its members, with some carriers parking aircraft due to insufficient crews. RAA has urged the FAA to consider whether marijuana policies unnecessarily restrict the qualified pilot pool.

Aerospace Medical Association

The AsMA provides scientific expertise on aviation medicine and includes many FAA Aviation Medical Examiners among its members. The association has called for research on cannabis impairment detection methods that could distinguish recent use from past use, noting that current urine testing cannot determine timing or impairment level.

Drug Policy Alliance and NORML

These advocacy organizations have pushed for marijuana policy reform across all federal agencies. Both submitted comments to the FAA arguing that cannabis prohibition in aviation is outdated, discriminatory, and not supported by safety data. They have pointed to policies in Canada and other countries that allow past marijuana use with appropriate abstinence periods.

Legal and Regulatory Framework

The FAA's marijuana standards rest on multiple layers of federal law, from constitutional authority through specific regulations and guidance documents. The constitutional foundation is the Commerce Clause, which grants Congress authority to regulate interstate commerce. The Supreme Court has consistently held that aviation is quintessentially interstate commerce, giving federal authorities broad regulatory power. In Montalvo v. Spirit Airlines, the First Circuit held that federal aviation safety regulations preempt state employment laws, including those protecting marijuana users. The Federal Aviation Act, codified at 49 U.S.C. § 44701 et seq., directs the FAA to promote aviation safety and grants the Administrator authority to prescribe regulations for pilot certification. Section 44703 specifically authorizes medical standards for airmen certificates, stating the Administrator may require applicants to demonstrate "physical and mental fitness." The Controlled Substances Act at 21 U.S.C. § 812 establishes the drug scheduling system that formerly classified marijuana as Schedule I and now places it in Schedule III. Schedule III substances may be prescribed by licensed practitioners and have recognized medical uses, but remain controlled substances subject to DEA regulation. The Omnibus Transportation Employee Testing Act of 1991, codified at 49 U.S.C. § 45102, mandates that the FAA establish drug testing programs for safety-sensitive aviation employees. The statute requires testing for marijuana among other substances and authorizes the Administrator to take certificate action based on positive tests. Implementing regulations appear in multiple sections of the Code of Federal Regulations. Part 67 establishes medical standards for airmen, with Section 67.307 listing "substance dependence" and "substance abuse" as specifically disqualifying conditions. Part 120 prescribes drug and alcohol testing requirements for certificate holders, including airlines and repair stations. Part 121 and Part 135 contain additional requirements for air carrier operations. The DOT drug testing regulations at 49 CFR Part 40 establish the specific procedures for collection, testing, and reporting. Subpart R addresses the consequences of positive tests, requiring immediate removal from safety-sensitive functions. The regulations specify that testing detects marijuana metabolites (THC-COOH) at a cutoff of 50 ng/mL for initial screening and 15 ng/mL for confirmation. FAA guidance documents provide additional detail. The Guide for Aviation Medical Examiners instructs examiners to defer or deny medical certificates for applicants with substance abuse histories. The agency defines substance abuse broadly to include any use of illegal drugs, meaning a single marijuana use technically constitutes abuse under FAA standards. Advisory Circular 120-114, "Air Carrier Drug and Alcohol Testing Programs," provides guidance to airlines on implementing testing requirements. The circular emphasizes that state marijuana laws do not affect federal testing obligations or the consequences of positive tests. The legal framework also includes international standards. The International Civil Aviation Organization, a United Nations agency, publishes Standards and Recommended Practices that influence national regulations. ICAO Annex 1 addresses personnel licensing and includes provisions on psychoactive substances, though it allows states flexibility in implementation. Several court cases have shaped the legal landscape. In Bogart v. FAA, the Ninth Circuit upheld the agency's authority to revoke a pilot certificate based on marijuana use, rejecting arguments that medical necessity should provide a defense. In Stein v. FAA, an administrative law judge held that CBD use was not a mitigating factor for a positive THC test. The Americans with Disabilities Act provides no protection for marijuana use, even when medically authorized, because the ADA specifically excludes current illegal drug use from its protections under 42 U.S.C. § 12114. Courts have consistently held that this exclusion applies to marijuana regardless of state legalization.

Current Standards and Testing Protocols

The FAA's existing marijuana policy operates through medical certification requirements, drug testing mandates, and enforcement procedures that together create a comprehensive prohibition. All pilots must hold a medical certificate appropriate to their operations. First-class medicals are required for airline transport pilots, second-class for commercial pilots, and third-class for private pilots (though the BasicMed alternative allows some private pilots to fly without an FAA medical). The medical application, FAA Form 8500-8, asks applicants about substance use and requires disclosure of any drug-related arrests or convictions. Aviation Medical Examiners conduct the physical examinations and review applications. When an applicant reports marijuana use or a positive drug test, the examiner must defer the application to the FAA's Aerospace Medical Certification Division in Oklahoma City. The division then requests detailed documentation, including substance abuse evaluations, treatment records, and abstinence verification. For pilots with past marijuana use, the FAA typically requires a minimum two-year abstinence period before considering certification. During this period, applicants must undergo random observed drug testing, typically 10-12 tests annually. They must also complete a substance abuse evaluation by a qualified professional and may need psychological assessment. The drug testing program operates separately from medical certification. Airlines, repair stations, and other certificate holders must establish FAA-approved testing programs covering all safety-sensitive employees. This includes pilots, flight attendants, mechanics, dispatchers, and ground security coordinators. Testing occurs in five circumstances: pre-employment (before first performing safety-sensitive functions), random (at least 25% of covered employees annually for drugs, 10% for alcohol), reasonable suspicion (when a supervisor observes behavior suggesting drug use), post-accident (after accidents meeting specified criteria), and return-to-duty (before resuming safety-sensitive work after a positive test). Urine samples are collected under direct observation for return-to-duty and follow-up tests, and under indirect observation for other tests. Samples are sent to HHS-certified laboratories that use immunoassay screening followed by gas chromatography/mass spectrometry confirmation. The testing detects THC-COOH, the primary marijuana metabolite, which can remain detectable for days to weeks after use depending on frequency and individual metabolism. A confirmed positive test results in immediate removal from safety-sensitive duties and triggers FAA enforcement action. For pilots, this typically means emergency revocation of all certificates. The pilot may request a hearing before an NTSB administrative law judge, but the burden is on the pilot to prove they did not use marijuana or that the test was flawed. Reinstatement after a positive test requires completing a substance abuse program, demonstrating sustained abstinence through random testing (typically two years), and obtaining a special issuance medical certificate. The process often takes three to five years and costs $15,000-$30,000 in testing, evaluations, and legal fees. The FAA also takes action based on drug-related motor vehicle offenses. Pilots must report any drug-related driving action within 60 days on FAA Form 8710-13. A marijuana DUI triggers certificate suspension or revocation even without a positive aviation drug test.

Scientific Evidence on Cannabis and Aviation Safety

Research on marijuana's effects on pilot performance shows impairment during acute intoxication but limited data on residual effects and no validated impairment testing for workplace use. Studies conducted in flight simulators have consistently found that THC impairs aviation-relevant skills during the period of acute intoxication. A 2014 study published in Drug and Alcohol Dependence found that pilots who smoked marijuana showed significant decrements in flight performance for up to four hours, with effects most pronounced in the first hour. Impaired functions included lateral tracking, altitude maintenance, and response to emergency situations. However, simulator studies also show that performance typically returns to baseline within 24 hours of use. A 1994 FAA-funded study found no residual impairment 24 hours after marijuana smoking, even though THC metabolites remained detectable in urine. This creates a disconnect between drug testing (which detects past use) and impairment assessment (which measures current fitness). No validated field sobriety test exists for marijuana impairment comparable to breathalyzers for alcohol. Blood THC levels correlate poorly with impairment because tolerance varies widely among users, and THC is rapidly distributed to fatty tissues. Some jurisdictions have attempted to establish per se THC limits (typically 5 ng/mL in blood), but research questions whether such thresholds reliably indicate impairment. The National Academies of Sciences, Engineering, and Medicine published a comprehensive cannabis review in 2017 concluding that substantial evidence supports acute cannabis impairment of cognitive and motor functions, but that evidence is limited regarding long-term effects on cognition in adult users. The report noted that current detection methods cannot determine recent use or impairment level. Aviation-specific safety data is limited. The FAA's Civil Aerospace Medical Institute has published studies on drug findings in fatal aviation accidents. A 2020 analysis found THC in 3.9% of pilots killed in general aviation accidents between 2013 and 2018. However, the presence of THC does not establish causation, as post-mortem testing cannot determine whether the pilot was impaired at the time of the accident. The National Transportation Safety Board's accident database shows marijuana as a contributing factor in a small number of cases. A 2019 NTSB analysis identified 18 accidents between 2008 and 2017 where pilot marijuana use was cited as contributory. In most cases, other factors such as poor weather, inadequate training, or mechanical issues were also present. International aviation authorities have adopted varied approaches based on similar scientific evidence. Transport Canada allows pilots with past marijuana use to be certified after demonstrating six months of abstinence and completing assessment. The United Kingdom's Civil Aviation Authority similarly permits certification after an abstinence period and evaluation. Australia requires 90 days of documented abstinence. These international policies reflect a distinction between past use (which may indicate risk but does not prove current impairment) and recent use (which may indicate impairment or poor judgment). The FAA's lifetime prohibition for any use is more restrictive than most comparable aviation authorities.

What Experts Say

Aviation medicine specialists, safety experts, and policy analysts have offered diverse perspectives on how the FAA should respond to marijuana rescheduling. Dr. Michael Berry, a former FAA Federal Air Surgeon, stated in a 2026 interview that any policy changes must prioritize safety above all other considerations. According to Berry, the challenge is that current drug testing technology cannot distinguish between a pilot who used marijuana weeks ago and one who used it the night before a flight. He emphasized that until impairment-based testing becomes available, the FAA faces difficult choices between workforce needs and safety assurance. The Aerospace Medical Association's president, Dr. James Fraser, said in July 2026 that the association supports evidence-based policy development. Fraser noted that rescheduling to Schedule III acknowledges medical uses but does not resolve questions about impairment detection or safety risk. He called for research funding to develop better testing methods and to study whether pilots with past marijuana use have different accident rates than those without such history. Aviation safety consultant John Cox, a former airline pilot and accident investigator, stated that the industry's safety culture depends on clear, enforceable standards. According to Cox, any ambiguity about drug policies could undermine the zero-tolerance approach that has contributed to commercial aviation's exceptional safety record. He argued that if the FAA modifies its marijuana standards, the changes must be accompanied by robust education and clear bright lines. Dr. Joanna Katzman, a professor of psychiatry at the University of New Mexico who has studied cannabis use disorders, said that the FAA's current approach does not distinguish between occasional past use and substance abuse disorders. According to Katzman, evidence-based assessment would focus on patterns of use, consequences, and current functioning rather than applying lifetime bans for any use. She noted that many individuals who used marijuana in college or experimented briefly pose no greater safety risk than those who never used it. Mark Baker, president of the Aircraft Owners and Pilots Association, stated in congressional testimony that the pilot shortage is real and that unnecessarily restrictive policies exacerbate workforce challenges. According to Baker, the FAA should examine whether its marijuana standards are appropriately calibrated to actual safety risks or whether they reflect outdated assumptions from the drug war era. He emphasized that AOPA supports maintaining high safety standards while ensuring policies are evidence-based. Paul Rinaldi, former president of the National Air Traffic Controllers Association, said that controller staffing is critically low at many facilities and that hiring barriers should be minimized consistent with safety. According to Rinaldi, the FAA should consider whether past marijuana use should be permanently disqualifying or whether candidates who demonstrate current fitness should be eligible. He noted that the agency already grants special issuance medicals for conditions like diabetes and depression, showing that risk management is possible for complex medical issues. Dr. Bertha Madras, a Harvard Medical School professor who served on the President's Commission on Combating Drug Addiction, argued that marijuana rescheduling should not lead to relaxed aviation standards. According to Madras, cannabis affects cognitive functions essential to aviation safety, including attention, working memory, and executive function. She stated that the precautionary principle supports maintaining prohibition for safety-sensitive positions even if some qualified candidates are excluded. Kevin Sabet, president of Smart Approaches to Marijuana, said that the aviation industry should maintain zero-tolerance policies regardless of rescheduling. According to Sabet, marijuana is significantly more potent than in previous decades, with THC concentrations in products often exceeding 20% compared to 3-4% in the 1990s. He argued that this increased potency heightens safety concerns and that aviation should remain a marijuana-free profession.

State-by-State Medical Marijuana Programs

Thirty-eight states have legalized medical marijuana, creating a patchwork of programs that conflict with federal aviation standards.

California

California's Proposition 215, passed in 1996, established the nation's first medical marijuana program. The state's current Medical Marijuana Program allows patients with physician recommendations to possess up to eight ounces and cultivate up to six mature plants. Qualifying conditions include cancer, AIDS, chronic pain, and any condition for which marijuana provides relief. Despite state protection, California pilots who use medical marijuana face FAA certificate revocation.

Colorado

Colorado legalized medical marijuana in 2000 and adult-use in 2012. The state's medical program requires physician certification for specific debilitating conditions including cancer, glaucoma, HIV/AIDS, and PTSD. Patients may possess up to two ounces. Colorado has approximately 80,000 registered medical marijuana patients, some of whom hold pilot certificates but cannot legally use their state-authorized medicine without losing FAA certification.

Florida

Florida voters approved medical marijuana in 2016 through Amendment 2. The state's program, among the nation's largest, has enrolled more than 800,000 patients. Qualifying conditions include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Florida's large population of pilots, particularly in South Florida's aviation hub, creates significant tension between state medical authorization and federal aviation prohibition.

Illinois

Illinois legalized medical marijuana in 2013 and adult-use in 2020. The medical program covers more than 40 qualifying conditions and has approximately 150,000 registered patients. The state's program explicitly states that it does not require employers to accommodate marijuana use, and federal law preempts state protections for aviation workers.

Massachusetts

Massachusetts voters approved medical marijuana in 2012 and adult-use in 2016. The state's medical program requires physician certification for conditions including cancer, HIV/AIDS, hepatitis C, ALS, Crohn's disease, Parkinson's disease, and MS. Patients may possess up to 10 ounces. Massachusetts has a significant aviation industry, including major airports and numerous corporate flight departments, where pilots face conflicts between state and federal law.

Michigan

Michigan legalized medical marijuana in 2008 and adult-use in 2018. The medical program covers debilitating conditions including cancer, HIV/AIDS, hepatitis C, ALS, and chronic pain. Patients may possess 2.5 ounces and cultivate 12 plants. Michigan's program explicitly states that it does not permit operating aircraft while under the influence, but the FAA's prohibition extends beyond impaired operation to any use.

New York

New York established a medical marijuana program in 2014 and legalized adult-use in 2021. The medical program covers serious conditions including cancer, HIV/AIDS, ALS, Parkinson's disease, MS, epilepsy, IBD, neuropathy, and PTSD. New York's aviation workforce, including pilots based at JFK, LaGuardia, and Newark airports, faces the same federal-state conflict as other states.

Ohio

Ohio legalized medical marijuana in 2016, with dispensaries opening in 2019. Qualifying conditions include cancer, chronic pain, epilepsy, fibromyalgia, HIV/AIDS, IBD, MS, Parkinson's disease, PTSD, and traumatic brain injury. Ohio has approximately 220,000 registered patients. The state's program does not protect employees in safety-sensitive positions, and federal aviation law preempts any state employment protections.

Pennsylvania

Pennsylvania's medical marijuana program, established in 2016, covers 23 serious medical conditions including cancer, epilepsy, HIV/AIDS, ALS, Crohn's disease, and PTSD. The state has enrolled more than 400,000 patients. Pennsylvania law explicitly states that nothing requires employers to accommodate marijuana use, and federal aviation regulations supersede state protections.

Texas

Texas has a limited medical marijuana program, the Compassionate Use Program, allowing low-THC cannabis (up to 1% THC) for specific conditions including epilepsy, autism, cancer, and PTSD. Despite the program's restrictions, FAA policy treats any marijuana use as disqualifying, creating conflicts for Texas pilots with qualifying conditions.

Market and Business Implications

The FAA's marijuana policy review carries significant implications for aviation workforce economics, insurance markets, and the broader cannabis industry's legitimacy. The pilot shortage has created intense competition for qualified candidates. Regional airlines have increased first-year pay from approximately $20,000 in 2015 to $50,000-$80,000 in 2026, with some offering signing bonuses exceeding $20,000. Major airlines have reduced minimum flight time requirements and expanded recruitment efforts. Despite these measures, the Regional Airline Association projects a shortfall of 3,000-5,000 pilots annually through 2030. If the FAA were to allow pilots with past marijuana use to be certified after demonstrating abstinence, the qualified candidate pool could expand significantly. A 2025 survey by the University of North Dakota's aviation program found that 18% of aviation students reported past marijuana use, with most occurring before entering flight training. Under current FAA policy, these students face potential permanent disqualification if their use is discovered during medical certification or drug testing. Air traffic controller recruitment faces similar constraints. The FAA's Academy accepts approximately 1,800